Author name: DrugChatter

Every time ChatGPT answers a drug question, it may be doing something no FDA-approved ad campaign ever could — and […]

The standard pharmacovigilance process has a timing problem Adverse events travel faster than case reports. A patient posts about a

There’s a particular genre of drug question that never goes out of style: “What happens if I mess this up?”

There’s a pattern to mass adoption in pharma. First comes clinical data, then prescriber uptake, then—inevitably—the public internet asking the

By the time your next drug launches, a chatbot will already have an opinion about it — and 40 million

Why Pharmaceutical Companies Must Monitor AI Mentions Right Now There is a new drug representative calling on your patients and

How pharmaceutical brands are losing control of their narrative to AI answer engines — and the monitoring infrastructure they need

The Question Every Pharma Brand Team Is Ignoring Somewhere right now, a 54-year-old with newly diagnosed Type 2 diabetes is

What pharma’s regulatory, medical affairs, and brand teams need to do right now There is a scenario playing out across

Pharmaceutical brands are losing control of their product narrative — not in the press, not at the pharmacy counter, but

The Problem No One Is Watching Closely Enough Somewhere between a patient typing symptoms into a chatbot and a physician

The Invisible Conversation Shaping Your Drug’s Reputation Somewhere right now, a patient is asking an AI chatbot whether their statin